197 related articles for article (PubMed ID: 36291122)
1. Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years.
Carmina E; Longo RA
Cells; 2022 Oct; 11(20):. PubMed ID: 36291122
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes.
Carmina E; Lobo RA
J Endocrinol Invest; 2007 Feb; 30(2):111-6. PubMed ID: 17392600
[TBL] [Abstract][Full Text] [Related]
3. DHEA, DHEAS and PCOS.
Goodarzi MO; Carmina E; Azziz R
J Steroid Biochem Mol Biol; 2015 Jan; 145():213-25. PubMed ID: 25008465
[TBL] [Abstract][Full Text] [Related]
4. Is it useful to measure DHEAS levels in PCOS?
Boucher H; Robin G; Ribière L; Martin C; Espiard S; Catteau-Jonard S
Ann Endocrinol (Paris); 2024 Apr; 85(2):95-99. PubMed ID: 38360397
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
6. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
7. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
8. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
9. Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome.
Medeiros SF; Barbosa BB; Medeiros MAS; Yamamoto AKLW; Yamamoto MMW
Rev Bras Ginecol Obstet; 2022 Feb; 44(2):142-153. PubMed ID: 35213912
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
Kumar A; Woods KS; Bartolucci AA; Azziz R
Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
[TBL] [Abstract][Full Text] [Related]
11. Impact of dehydroepiandrosterone sulfate and free androgen index on pregnancy and neonatal outcomes in PCOS patients.
Zhao W; Li Z; Cai B; Zhou C; Mai Q
Reprod Biol Endocrinol; 2024 Apr; 22(1):43. PubMed ID: 38627777
[TBL] [Abstract][Full Text] [Related]
12. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
[TBL] [Abstract][Full Text] [Related]
14. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women.
Elhassan YS; Idkowiak J; Smith K; Asia M; Gleeson H; Webster R; Arlt W; O'Reilly MW
J Clin Endocrinol Metab; 2018 Mar; 103(3):1214-1223. PubMed ID: 29342266
[TBL] [Abstract][Full Text] [Related]
15. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population.
Baldani DP; Skrgatić L; Simunić V; Zlopasa G; Canić T; Trgovcić I
Coll Antropol; 2013 Jun; 37(2):477-82. PubMed ID: 23940993
[TBL] [Abstract][Full Text] [Related]
17. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
[TBL] [Abstract][Full Text] [Related]
18. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?
Kaltsas GA; Mukherjee JJ; Kola B; Isidori AM; Hanson JA; Dacie JE; Reznek R; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2003 Jul; 59(1):34-43. PubMed ID: 12807501
[TBL] [Abstract][Full Text] [Related]
19. Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome.
Li Y; Zhai Y; Li L; Lu Y; Su S; Liu Y; Xu Z; Xin M; Zhang Q; Cao Z
Front Endocrinol (Lausanne); 2022; 13():881740. PubMed ID: 35757414
[TBL] [Abstract][Full Text] [Related]
20. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.
Rosenfield RL; Mortensen M; Wroblewski K; Littlejohn E; Ehrmann DA
Hum Reprod; 2011 Nov; 26(11):3138-46. PubMed ID: 21908468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
